representation that the cited references have effective dates early enough to be "prior and within the meaning of 35 U.S.C. sections 102 or 103.

CITED REFERENCES is intended as to the relative importance of any portion of the references. This Statement not a

U.S. PATENT APPLICATION DOCUMENTS

No.		Document Number	Filing Date	Name
1.	<u> </u>	60/101,074	9/21/98	Hartmann, et al.
2.	_ M	60/082,404	4/20/98	Thompson et al.
3.	4	09/406,643	9/27/99	Warburg

U. S. PATENT DOCUMENTS

No.	Document Number	Name	Publication Date if Appropriate	
41	4,987,071	Cech et al.	1/22/91	
5. }	5,334,711	Sproat et al.	8/2/94	
6.	5,525,468	McSwiggen	6/11/96	
7.	5,624,803	Noonberg et al.	4/29/97	
8.	5,627,053	Osman et al.	5/6/97	
9.	5,631,359	Chowrira et al.	5/20/97	
10.	5,633,133	Long et al.	5/27/97	
11.	5,672,695	Eckstein et al.	9/30/97	
12.	5,716,824	Beigelman et al.	2/10/98	
13.	5,849,902	Arrow et al.	12/15/98	
14. W	6,001,311	Brennan	12/4/99	

FOREIGN PATENT DOCUMENTS

No.	Document Number	Name	Date	Country
15. I A	0 360 257 A2	Hampel et al.	28.03.90	EO

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606 Telephone: (312) 913-0001

MBHB00,814-A RPI NO. 400.034 S/N: 09/927,046 Filing Date: 08/09/01

6 2001 G			TECH	CENTER 1600/2
ADEMARKS	Document Number	Name	Date	Country
16	91/03162	Rossi et al.	21.03.91	WO/PCT
17.	92/07065	Eckstein et al.	30.04.92	WO/PCT
18.	93/15187	Usman et al.	05.08.93	WO/PCT
19.	93/23057	Thompson et al.	25.11.93	WP/PCT
20.	93/23569	Draper et al.	25.11.93	WO/PCT
21.	94/02595	Sullivan et al.	03.02.94	WO/PCT
22.	95/04818	Draper et al.	16.02.95	WO/PCT
23.	95/11304	Usman et al.	27.04.95	WO/PCT
24.	95/13380	Draper et al.	18.05.95	WO/PCT
25.	95/23225	Stinchcomb et al.	31.08.95	WO/PCT
26.	96/10390	Ansell et al.	11.04.96	WO/PCT
27.	96/10391	Choi et al.	11.04.96	WO/PCT
28.	96/10392	Holland et al.	11.04.96	WO/PCT
29.	96/18736	Beigelman et al.	20.06.96	WO/PCT
30.	96/22689	Pyle et al.	01.08.96	WO/PCT
31	97/26270	Wincott et al.	24.07.97	WO/PCT
32.	97/35562	Illum et al.	02/10/97	WO/PCT
33.	98/13526	Woolf	02.04.98	WO/PCT
34.	98/28317	rpelsky et al.	02.07.98	WO/PCT
35.	98/43993	eaker	08.10.98	WO/PCT
36.	98/50530	Jarvis et al.	12.11.98	WO/PCT
37.	98/58058	Ludwig et al.	23.12.98	WO/PCT
38.	99/04819	Klimuk et al.	04.02.99	WO/PCT
39.	99/05094	Beigelman et al.	22.07.98	WO/PCT
40.	99/16871	Eckstein et al.	08.04.99	WO/PCT
41	99/44620	Holroyd et al.	10/09/99	WO/PCT

Charles and Statement

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606 Telephone: (312) 913-0001 MBHB00,814-A RPI NO. 400.034 S/N: 09/927,046 Filing Date: 08/09/01



6 2002	TECH CENTER 10				
DEMINE.	Document Number	Name	Date	Country	
42.M	99/54459	Thompson et al.	28.10.99	WO/PCT	
43. (99/55857	Beigelman et al.	28.04.99	WO/PCT	
44.	99/60010	Bennett et al.	25.11.99	WO/PCT	
45.	99/60166	Bennett et al.	25/11/99	WO/PCT	

OTHER DOCUMENTS

No.	
46.W	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," Science 271:1410-1413 (1996)
47.	Akhtar and Juliano, "Cellular uptake and intracellular fate of antisense oligonucleotides," Trends in Cell Biology 2:139-144 (1992)
48	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <u>Nucleic Acids Research</u> 26:4910-4916 (1998)
49.	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <u>Biochemistry</u> 34:6504-6512 (1995)
50.	Beaudry et al., "Directed Evolution of an RNA Enzyme," Science 257:635-641 (1992)
51	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <u>J. Biol. Chem.</u> 270:25702-25708 (1995)
52	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," Nucleosides & Nucleotides 16:951-954 (1997)
53.	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Aproach to Iterative Solid-Phase Synthesis," Bioconjugate Chem. 8:204-212 (1997)
54.	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," EBMO J. 12:2567-2574 (1993)
55.	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA- catalyzed clevage and ligation reactions," Genes & Development 6:129-134 (1992)
56.	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the Tetrahymena Ribozyme," Biochemistry 35:648-658 (1996)
57.	Boado, "Antisense drug delivery through the blood-brain barrier," Advanced Drug Delivery Reviews 15:73-107 (1995)
58. V	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago, IL 60606 Telephone: (312) 913-0001



DV 8	TECH CENTER 16	han ianaa
HAD	IEUN UEINIEM I	00/2900
739.M	Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a	
	fusogenic peptide," Nucleic Acids Research 22:4681-4688 (1994)	
60.	Breaker et al., "A DNA enzyme with Mg ² -dependent RNA phosphoesterase activity,"	
1-1-1	<u>Chemistry & Biology</u> 2(10):655-660 (1995)	
61.	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus	
	iterative selection methods," <u>TIBTECH</u> 12:268-275 (1994)	
62.	Breaker, "Are engineered proteins getting competition from RNA?" Current Opinion in	
	Biotechnology 7:442-448 (1996)	
63.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to	
1 \}	Automated Combinatorial Solid-Phase Organic Synthesis," Biotechnology and Bioendineering	
1	(Combinatorial Chemistry) 61:33-45 (1998)	
64.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates,"	
65.	Biochemistry 35:14090-14097 (1996) (volume no mistakenly listed as 6)	
03.	Burlina et al., "Chemical Engineering of Rnase Resistant and Catalytically Active	
	Hammerhead Ribozymes," Bioorganic & Medicinal Chemistry 5:1999-2010 (1997)	
66.	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," Methods in Enzymology 211:3-19 (1992)	
67.	Cech, "Ribozymes and Their Medical Implications," JAMA 260:3030-3034 (1988)	
68.	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the	
00.	hammerhead ribozyme domain," <u>Nucleic Acids Research</u> 23(20):4092-4096 (1995)	
69.		
109.	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently	
	Sequenced HIV-1 Isolates," Nucleic Acids Research 20:4581-4589 (1992)	
70.	Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis	
1 /0.	Delta Virus Self-Processing Ribozyme Cassettes," J. Biol. Chem. 269:25856-25864 (1994)	
71.	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," Nature	
1 ' 1	354:320-322 (1991)	
72.	Christoffersen and Marr, "Riobozymes as Human Therapeutic Agents," J. Med. Chem.	
	38:2023-2037 (1995) (also referred to as Christofferson and Marr)	
73.	Christofferson et al., "Application of computational technologies to ribozyme biotechnology	
1 11	products," <u>Journal of Molecular Structure (Theochem)</u> 311:273-284 (1994) (Christoffersen)	
74.	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived	
	From Neurospora VS RNA," Biochemistry 32:2795-2799 (1993)	
75.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function,"	
1 !!	<u>Trends In Genetics</u> 12:510-515 (1996)	
76.	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense	
	Oligonucleotides," Advances in Pharmacology 40:1-49 (1997)	
77.	Crooke, "Antisense Therapeutics," Biotechnology and Genetic Engineering Reviews 15:121-	
	157 (1998)	
78.	Cunningham et al., "Cloning of an Epithelial Chloride Channel from Bovine Traches," J. Biol.	
$\Box M$	<u>Chem</u> , 270: 31016-31026 (1995).	

RECEIVED

APR 0 9 2002

TECH CENTER 1600/2900

Ì	No	Ż	
4			Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative
	7	\square	Analysis of in Vitro Reaction Rates and Products," J. Mol. Biol. 256:31-49 (1996)
j	80.		Dreyfus, "Restriction Ribozymes?" Einstein Quarterly Journal of Biology and Medicine 6:92-
ı			93 (1988)
4	81.		Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of
i	- 1	Į	Human Immunodeficiency Virus Type I Expression," Journal of Virology 66:1432-1441
1	- 1		(1992)
Į	82		Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides,"
ı			Proc. Natl. Acad. Sci. USA 89:504-508 (1992)
Į	83.		Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and
Į			Function," Biopolymers 48:39-55 (1998)
Į	84.	ļ	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick
ı			hydrogen-bonding rules," Nature 365:566-568 (1993)
	85.	-	Eible et al., "Cloning and Characterization of Lung-Endothelial Cell Adhesion Molecule-1
1			Suggest It Is an Endothelial Chloride Channel," J. Biol. Chem., 272: 27853-27861 (1997).
İ	86.	- 1	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of
ı			Bacteriophage T7 RNA Polymerase in Mammalian Cells," Proc. Natl. Acad. Sci. USA
١		_	87:6743-6747 (1990)
ı	87	ľ	Emerich et al., "Biocompatability of Poly (DL-Lactide-co-Glycolide) Microsheres Implanted
١			Into the Brain," Cell Transplantation 8:47-58 (1999)
1	88		Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco
		-	ringspot virus complementary RNA," Gene 82:53-61 (1989)
١	89.	-1	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated
Ì	1	. 1	with cationic lipids toward immune effector cells," Biochimica et Biophysica Acta 1329:345-
ŀ		\vdash	356 (1997)
1	90.		Forster and Altman, "External Guide Sequences for an RNA Enzyme," Science 249:783-786
ŀ		┨	(1990)
ı	91.		Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," Proc.
ŀ	92.	╫	Natl. Acad. Sci. USA 83:9373-9377 (1986)
1	92.		Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA
ļ			Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u>
ŀ	93.	╫	21:2867-2872 (1993) Good et al., "Expression of small, therapuetic RNAs in human nuclei," Gene Therapy 4:45-54
١	<i>9</i> 3.		(1997)
ŀ	94.	+	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme
١	<i>7</i> 4.		Required for Catalytic Cleavage of RNA," <u>Biochemistry</u> 34:4068-4076 (1995)
ł	95.	H	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar
1	75.		efficiency, and lack contacts with substrate 2'-hydroxyl groups," Chemistry & Biology 2:761-
	- 1		770 (1995)
	96.	7	Gruber et al., "Genomic Cloning, Molecular Characterization, and Functional Analysis of
1			Human CLCA1, the First Human Member of the Family of Ca ²⁺ -Activated Cl' Channel
1	h	Y	Proteins," Genomics, 54, 200-214 (1998)
•	٧		

. 45.60

. १,३१ र

RECEIVED

APR 0 9 2002

TECH CENTER 1600/2900

	No.	ی	TEOT OF THE TOTAL TEOT OF THE
RA	DBAN		Gruber et al., "The murine calcium-sensitive chloride channel (mCaCC) is widely expressed in
	L		secretory epithelia and in other select tissues," <u>Histochem. Cell Biol.</u> , 110, 43-49 (1998)
	98		Gruber et al., "Molecular Cloning and Transmemnbrane Structure of hCLCA2 from Human
		À	Lung, Trachea, and Mammary Gland,", Am. J. Physiol., 276: C1261-C1270 (1999)
ı	99.		Gruber et al., "Tumorigenicity of Human Breast Cancer is Associated with Loss of the Ca ²⁺ -
ļ			activated Chloride Channel CLCA2, Cancer Res., 59: 5488-5491 (1999).
i	100	.	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the
į			Enzyme," <u>Cell</u> 35:849-857 (1983)
	101	.	Guo and Collins, "Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme
ı			derived from Neurospora VS RNA," EMBO J. 14:368-376 (1995)
ı	102	.	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence."
Į	\perp		Biochemistry 28:4929-4933 (1989)
1	103	.	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence
1	_1	_	Requirement for Substrate RNA," Nucleic Acids Research 18:299-304 (1990)
ı	104	.	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P
1		_	RNA," <u>RNA</u> 1:210-218 (1995)
ľ	105	- 1	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense
ı	- 1	١	Oligonucleotides in Human Monocytes and Lymphocytes," The Journal of Pharmacology and
ļ		_	Experimental Therapeutics 285:920-928 (1998)
ı	106.	-	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of
ı		4	tobacco ringspot virus," Gene 82:43-52 (1989)
I	107.	-	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific
L		1	Endoribonuclease Activities," Nature 334:585-591 (1988)
ı	108		Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin
ŀ		4	Ribozymes," <u>Biochemistry</u> 34:15813-15828 (1995)
ı	109.		Herschlag and Cech, "Catalysis of RNA Cleavage by the Tetrahymena thermophila Ribozyme
۱			1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active
ŀ		_	Site," <u>Biochemistry</u> 29:10159-10171 (1990)
ı	110		Herschlag and Cech, "Catalysis of RNA Cleavage by the Tetrahymena thermophila Ribozyme.
ł			2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the
ŀ			Active Site," <u>Biochemistry</u> 29:10172-10180 (1990)
l	111		Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme
ŀ		4	Reaction," <u>Biochemistry</u> 33:3374-3385 (1994)
ı	112	1	Hertel et al., "Numbering System for the Hammerhead," Nucleic Acids Research 20:3252
ŀ			(1992)
l	113.		Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic
ŀ		$\sqcup I_{-}$	Methods," VCH, 331-417 (1995)
ı	114.	Ш	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene
۱		Ш	glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether, "Chem Pharm Bull
L		\coprod	43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	115.		Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and
L	M	1	Endogeneous Genes by Anti-Sense RNA," Science 229:345-352 (1985)



OIPE CO. 6. SEED 2. 6 TORSE

TECH CENTER 4 600/2900

116.	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," Proc. Natl. Acad. Sci. USA 86:7706-7710 (1989)
117	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," <u>Nucleic Acids Research</u> 17:1371-1377 (1989) (also referred to as Jefferies)
118	Jolliet-Riant and Tillement, "Drug transfer acorss the blood-brain barrier and improvement of brain delivery," Fundam. Clin. Pharmacol. 13:16-26 (1999)
119.	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," Genes & Development 7:130-138 (1993)
120.	Joyce et al., "Amplification, mutation and selection of catalytic RNA," Gene 82:83-87 (1989)
121.	Joyce, "Directed Molecular Evolution," Scientific American 267:90-97 (1992)
122.	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," Tetrahedron Letters 39:1131-1134 (1998)
123.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," Antisense Research & Development 2:3-15 (1992)
	Kent et al., "Lung Disease in Mice with Cystic Fibrosis,", J. Clin. Invest., 100(12): 3060-3069 (1997).
125.	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of <i>Tetrahymena</i> ," Proc. Natl. Acad. Sci. USA 84:8788-8792 (1987)
126.	Knitt et al., "ph Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconvential Origin of an Apparent pK ₈ ," <u>Biochemistry</u> 35:1560-1570 (1996)
127.	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisistsed; the NIH rule", Nucleic Acids Research, 26(18):4116-4120 (1998).
128.	Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," <i>Blood</i> 91:852-862 (1998)
129.	Kumar and Ellington, "Artificial evolution and natural ribozymes," <u>FASEB J.</u> 9:1183-1195 (1995)
130.	Lasic and Papahadjopoulos, "Liposomes Revisited," Science 267:1275-1276 (1995)
131.	UHuillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α- Lactalbumin mRNA Levels in C1271 Mouse," EMBO J. 11:4411-4418 (1992)
132.	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size," Nucleic Acids Research 24:835-842 (1996)
133. I	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," Biochemistry 34:14394-14399 (1995)
134. I	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)
135. I	Limbach et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Research 12(12):2183-2196 (1994)
136. I	isacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," J. Mol. Biol. 235:1206-1217 (1994)



TECH	CENTER	T16011/2000
	OFILE	I UUMMEJ KI

	None	TEON CENTER 163
4	RADE	and the state of t
١	N.	Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for
Į	K	Gene Therapy in AIDS," Proc. Natl. Acad. Sci. U.S.A. 90:8000-8004 (1993)
I	138.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," J. Biol. Chem.
ı		270(42):24864-24870 (1995)
139.		Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular
ı		hammerhead RNAs with stem II deletions," Proc. Natl. Acad. Sci. USA 91:6977-6981 (1994)
ľ	140.	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by
Į		Liposomes and Immunoliposomes," Leukemia Research 20:925-930 (1996)
ı	141.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense
l		RNA," Proc. Natl. Acad. Sci. USA 83:399-403 (1986)
ı	142.	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," RNA
L		2:395-403 (1996)
ı	143.	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," American Chemical
L		Society, pp. 24-39 (1994)
ı	144.	Metzger and Nyce, "Molecular mechanisms in allergy and clinical immunology," J. Allergy
L		Clin. Immunol., 104(2, Pt. 1), 260-266 (1999)
L	145.	Michel and Westhof, "Slippery substratrates," Nat. Struct. Biol. 1:5-7 (1994)
I	146.	Michel et al., "Structure and Activities of Group II Introns," Annu. Rev. Biochem. 64:435-461
L		(1995)
147.		Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme
ı		that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and
L		Structure/Function Relationships," Biochemistry 34:2965-2977 (1995)
ľ	148.	Milligan and Uhlenbeck, "Synthesis of Small RNAs Using T7 RNA Polymerase." Methods
L		Enzymol. 180:51-62 (1989)
ı	149.	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic
		plants," Proc. Natl. Acad. Sci. USA 93:6780-6785 (1996)
	150.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the
L		Splice Sites," <u>Science</u> 256:992-996 (1992)
ı	151.	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," Critical
L		Reviews in Oncogenesis 7:151-190 (1996)
ı	152.	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for
L		Improved Cleavage," Biochemistry 33:1271-1277 (1994)
	153.	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA
Ļ		Molecules," Ann. Rev. Biochem. 44:273-293 (1975)
ı	154.	Noonberg et al., In vivo generation of highly abundant sequence-specific oligonucleotides for
L		antisense and triplex gene regulation," Nucleic Acids Research 22(14):2830-2836 (1994)
١	155.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun'
L		Type Ribozyme-trimming Plasmid," Nucleic Acids Symp. Ser. 27:15-16 (1992)
ĺ	156.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin
L	N	Ribozyme," Proc. Natl. Acad. Sci. USA 89:10802-10806 (1992)
L	157.	Orgel, "Selection in vitro," Proc. R. Soc. London B. 205:435-442 (1979)

KECEIVED

APR 0.9, 2002

TECH CENTER 1600/2900

Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the No. M Rnase P and pre-tRNA," Proc. Natl. Acad. Sci. USA 92:12510-12514 (1995) Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," Proc. Natl. Acad. Sci. USA 92:5592-5596 (1995) 160. Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," Nature 344:565-567 (1990) (often mistakenly listed as Perrault) Perrotta and Been, "A pseudoknot-like structure required for efficeint self-cleavage of hepatitis 161. delta virus RNA," Nature 350:434-436 (1991) Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," Biochemistry 31:16-21 (1992) 163. Picken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," Science 253:314-317 (1991) 164. Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," Nucleic Acids Research 21:4253-4258 (1993) Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: 165. Quantitation of Interdomain Binding and Reaction Rate," Biochemistry 33:2716-2725 (1994) 166. Ran and Benos, "Immunopurification and Structural Analysis of a Putative Epithelial C1-Channel Protein Isolated from Bovine Trachea," J. Biol. Chem, 267: 3618-3625 (1992) 167. Robertson et al., "Purification and Properties of a Specific Escherichia coli Riobnuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," J. Biol. Chem. 247:5243-5251 (1972) 168. Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," Aids Research and Human Retroviruses 8:183-189 (1992) 169. Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," Proc. Natl. Acad. Sci. USA 94:4262-4266 (1997) 170. Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" Science 247:1222-1225 (1990) Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In 171. Neurospora Mitochondria," Cell 61:685-696 (1990) 172. Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a Neurospora Mitochondrial Plasmid Transcript," Proc. Natl. Acad. Sci. USA 88:8826-8830 (1991) 173. Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," Proc. Natl. Acad. Sci. USA 88:10591-10595 174. Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using βcyanoethyl protected ribonucleoside phosphoramidites," Nucl Acids Res. 18:5433-5441 (1990) 175. Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," The Journal of Biological Chemistry 274:21783-21789 (1999) 176. Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," Nucleic Acids Research 24:573-581 (1996) Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed M mechanism for RNA catalytic cleavage," Cell 81:991-1002 (1995)

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, Fl. 32 Chicago II. 60606

300 South Wacker Drive, Fl. 32 Chicago, IL 60606 Telephone: (312) 913-0001 MBHB00,814-A RPI NO. 400.034 S/N: 09/927,046 Filing Date: 08/09/01



_	Trou and
No.	TECH CENTER 1600/2001
178.	Shabarova et al., "Chemical ligation of DNA: The first non-enyzmatic assembly of a
I M	biologically active gene," Nucleic Acids Research 19:4247-4251 (1991)
179.	Shapiro, "Animal Models for Chronic Obstructive Pulmonary Disease; Age of Klotho and
	Marlboro Mice," Am. J. Respir. Cell Mol. Biol., 22(1): 4-7 (2000).
180.	Stein, "Does antisense exist," Nature Medicine 1(11):1119-1121 (1995)
181.	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really
	Magical?" Science 261:1004-1288 (1993)
182.	Strobel et al., "Exocyclic Amine of the Conserved G-U Pair at the Cleavage Site of the
1	Tetrahymena Ribozyme Contributes to 5'-Splice Site Selection and Transition State
	Stabilization," Biochemistry 35:1201-1211 (1996)
183. \	Strobel et al., "Minor Groove Recognition of the Conserved G·U Pair at the Tetrahymena
	Ribozyme Reaction Site," Science 267:675-679 (1995)
184.	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-
	splicing," <u>Nature</u> 371:619-622 (1994)
185.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of
ļ	Viral RNA," <u>Science</u> 262:1566-1569 (1993)
186.	Szostak, "In Vitro Genes," TIBS 17:89-93 (1993)
187.	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used
1 /	both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences
	transcription vectors," Nucleic Acids Research 19:5125-5130 (1991)
188.	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro
	selection," RNA 3:914-925 (1997)
189.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-
100	based RNA polymerase III promoter," Nucleic Acids Research 23:2259-2268 (1995)
190.	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense
101	chimera," Proc. Natl. Acad. Sci. USA 90:1300-1304 (1993)
191.	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," J.
102	Am. Chem. Soc. 109:3783-3785 (1987)
192.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p.
	cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci.</i> USA 96:7053-7058 (1999)
193.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal
193.	
194.	cells in vivo," FEBS Letters 421:280-284 (1998) Uhlenbeck, "A Small Catalytic Oligoribonucleotide," Nature 328:596-600 (1987) (this is listed
194.	as Nature 327 in the various specifications, but it is actually 328)
195	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," Chemical
193	Reviews 90:544-584 (1990)
196	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," TIBS 17:334-339 (1992)
197	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," Annual Reports in
W	Medicinal Chemistry 30:285-294 (1995)
<u> </u>	113001011111 CHOINIGH Y 30.203-234 (1993)



APR 0 9 2002 TECH CENTER 1600/2900 ·

	TECH CENTER 1600/290
No.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-
198.	Usman et al., 'Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-
١.,	Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support:
ΙM	Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli
	Formylmethoionine tRNA," J. Am. Chem. Soc. 109:7845-7854 (1987)
199.\	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease
`	resistance," Nucleic Acids Syposium Series 31:163-164 (1994)
200.	Usman et al., "Hammerhead ribozyme engineering," Current Opinion in Structural Biology
<u> </u>	1:527-533(1996)
201.	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by in Vitro
	Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
202.	Van Doorninck et al., "A mouse model for the cystic fibrosis ΔF508 mutation," EMBO J.,
	14(18), 4403-11 (1995)
203.	Vassar et al., "β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the
	Transmembrane Aspartic Protease BACE," Science 286:735-741 (1999)
204.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," Nucleic
	Acids Research 21:3249-3255 (1993)
205.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu.
206	Rev. Biochem. 67:99-134 (1998)
206.	Vyle et al., "Sequence- and Strand-Specific Cleavage in Oligodeoxyribonucleotides and DNA
205	Containing 3'-Thiothymidine," Biochemistry 31:3012-3018 (1992)
207.	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes,"
200	Nucleic Acids Research 23(14):2677-2684 (1995)
208.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," Methods in
209.	Molecular Biology 74:59-69 (1997)
209.	Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research, " <u>Biopharm</u> , November 1994.
210.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human
210.	Immunodeficiency Virus Type 1," Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993)
211.	Yuan et al., "Targeted cleavage of mRNA by human RNase P," Proc. Natl. Acad. Sci. USA
211.	89:8006-8010 (1992)
212.	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the
	Tetrahymena ribozyme," Nucleic Acids Research 24:854-858 (1996)
213.	Zaug et al., "The <i>Tetrahymena</i> Ribozyme Acts Like an RNA Restriction Endonuclease,"
	Nature 324:429-433 (1986)
214.	Zeiher et al., "A Mouse Model for the ΔF508 Allele of Cystic Fibrosis," 1995, J. Clin Invest.,
	96(4), 2051-64
215.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA
[Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990)
216.	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease
	Involved in Intron Mobility," Cell 83:529-538 (1995)
217.	Zhu et al., Blocking of Lung Endothelial Cell Adhesion Molecule-1 (Lu-ECAM-1) Inhibits
N	Murine Melanoma Lung Metastasis,) 1992, J. Clin Invest., 89, 1718-1724





Sheet 1 of 1

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

Attv. Docket No. 00,814-A

Serial No. 09/927,046

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(400.034)Applicant:

James McSwiggen et al.

Filing Date: 8/09/2001

Group: 1646

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Trans	slation
							Yes	No
Λ/	1.	WO 98/32846	7/30/1998	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

<u></u>	2.	Genbank Accession No. AF039400, "Homo sapiens calcium-dependent chloride channel-1 (hCLCA1) mRNA, complete cds," December 14, 1998.
L A	3.	Ludwig et al., "Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine 15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17," Nucleic Acids Research 26(10):2279-2285 (1998).
A	4.	Vaish et al., "In vitro selection of a purine nucleotide-specific hammerhead-like ribozyme," Proc. Natl. Acad. Sci. USA 95:2158-2162 (1998).

	 ,	
EXAMINER	 DATE CONSIDERED/	/
	1/12	103

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boennen Hurbert & Berghoff 300 South Wacker Drive CHCAGO, BLINOIS 60506 TELEPHONE (312) 913-0001